2‐DG potently reduces expression of the fibrotic marker collagen I following TGF‐β1 treatment (Figure 1C), although given 2‐DG completely blocks glycolysis this would be an unsuitable therapeutic for SSc treatment. This evidence concerns the gene TGFB1 and systemic sclerosis.